title: Agonist- and T(H)2 cytokine-induced up-regulation of cysteinyl leukotriene receptor messenger RNA in human monocytes.
abstract: BACKGROUND
  The cysteinyl leukotrienes (CysLTs) are lipid mediators that have been implicated in the pathogenesis of allergic diseases, and their actions are mediated via specific receptors named CysLT1 receptor (CysLT1R) and CysLT2 receptor (CysLT2R). Little information is known about the role of T(H)2 cytokines in the regulation of both CysLT1R and CysLT2R expression.
  
  
  OBJECTIVE
  To investigate the possible modulation of both CysLT1R and CysLT2R messenger RNA (mRNA) expression, we have developed a real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) assay based on the TaqMan fluorescence method to quantify CysLT1R and CysLT2R mRNA in human monocytes.
  
  
  METHODS
  Human monocytes were stimulated with leukotriene D4 or interleukin (IL) 4 or IL-13, and the levels of CysLT1R and CysLT2R mRNA were measured by the quantitative RT-PCR.
  
  
  RESULTS
  CysLT1R and CysLT2R mRNA was increased after stimulation with leukotriene D4. CysLT1R mRNA was augmented 150-fold after treatment with IL-4; however, no significant increase was observed in CysLT2R mRNA level. IL-13 could induce a biphasic augmentation of CysLT1R mRNA level. In contrast to IL-4, IL-13 enhanced CysLT2R mRNA level, with a maximal effect at 2 hours of incubation.
  
  
  CONCLUSIONS
  CysLT1R and CysLT2R expression can be regulated by CysLT itself and T(H)2 cytokines at the transcriptional level.
authors.affiliation: Department of Otolaryngology, Sapporo Medical University, Chuo-ku, Sapporo, Japan. shira@sapmed.ac.jp
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shirasaki
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Seki
authors.forename: Manabu
authors.initials: M
authors.lastname: Fujita
authors.forename: Megumi
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Etsuko
authors.initials: E
authors.lastname: Kanaizumi
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Watanabe
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Himi
mesh_terms: D002478:Cells, Cultured; D016207:Cytokines / Q000494:pharmacology*; D005434:Flow Cytometry; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D018793:Interleukin-13 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D020024:Leukotriene Antagonists / Q000494:pharmacology; D017998:Leukotriene D4 / Q000494:pharmacology*; D008565:Membrane Proteins / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D009000:Monocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D011422:Propionates / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism*; D018077:Receptors, Leukotriene / Q000819:agonists / Q000235:genetics* / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013189:SRS-A / Q000031:analogs & derivatives / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
chemical_list: C071435:BAY u9773; D016207:Cytokines; D018793:Interleukin-13; D020024:Leukotriene Antagonists; D008565:Membrane Proteins; D011422:Propionates; D011804:Quinolines; D012333:RNA, Messenger; D018077:Receptors, Leukotriene; D013189:SRS-A; D015847:Interleukin-4; C059141:verlukast; D017998:Leukotriene D4; C412375:cysteinyl leukotriene receptor 2; C083169:leukotriene D4 receptor